



PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form ~~100-10~~ 100-10

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

1

1

5

Examiner Name	Not yet assigned
Attorney Docket Number	BBC-201

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	FOREIGN PATENT DOCUMENTS		Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear ²	T ³
		Foreign Patent Document Country Code ⁴ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	
DB		WO 02/100330	06-05-2002	Abbott Biotechnology Ltd.	
		WO 04/004633	04-24-2003	Abbott Biotechnology Ltd.	
↓		WO 04/016286	02-26-2004	Abbott Laboratories (Berm	
↓		WO 04/037205	05-06-2004	Abbott Biotechnology Ltd.	
DB		WO 97/29131	08-14-1997	BASF Aktiengesellschaft	

Examiner Signature /David Blanchard/ **Date Considered** 08/31/2006
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/623,076
Sheet	2	of	5	Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1644
				Examiner Name	Not yet assigned
				Attorney Docket Number	BBC-201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB		Agostini et al. "Expression of Tumor Necrosis Factor-Receptor Superfamily Members by Lung T Lymphocytes in Interstitial Lung Disease" (1996) Am J Respir Crit Care Med. 153:135	
		Anticevich SZ, et al. "Induction of Human Airway Hyperresponsiveness by Tumour Necrosis Factor-a" (1995) Eur J Pharmacol. 284:221-5	
		Bingisser, et al. "Apoptosis in Human Alveolar Macrophages is Induced by Endotoxin and is Modulated by Cytokines" (1996) Am J Respir Cell Mol Biol. 15:64	
		Bowden, D.H. "Unraveling Pulmonary Fibrosis: The Bleomycin Model" (1984) Lab. Invest. 50:487	
		Chadelat et al. "Expression of Insulin-like Growth Factors and Their Binding Proteins by Bronchoalveolar Cells from Children with and Without Interstitial Lung Disease" (1998)	
		Cohn, L., et al. "Induction of Airway Mucus Production by T Helper 2 (Th2) Cells: A Critical Role for Interleukin 4 in Cell Recruitment but not Mucus Production" (1997) J. Exp.	
		Coker et al. "Anticytokine Approaches in Pulmonary Fibrosis: Bringing Factors into Focus" (1997) Thorax. Mar;52(3):294-6	
		Corbett EL, et al. "Polymorphisms in the Tumor Necrosis Factor-a Gene Promoter may Predispose to Severe Silicosis In Black South African Miners" (2002) Am J Respir Crit Care M	
↓		Deurloo, D.T., et al. "CTLA4-IgG Reverses Asthma Manifestations in a Mild but Not in a More "Severe" Ongoing Murine Model" (2001) Am. J. Respir. Cell Mol. Biol. 25:751	
DB		de Godoy et al. "Elevated TNF-a Production by Peripheral Blood Monocytes of Weight-losing COPD Patients" Am J Respir Crit Care Med. 1996 Feb;153(2):633-7	

Examiner Signature	/David Blanchard/	Date Considered	08/31/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/623,076
				Filing Date	July 18, 2003
				First Named Inventor	S. Banerjee
				Art Unit	1644
				Examiner Name	Not yet assigned
Sheet	3	of	5	Attorney Docket Number	BBC-201

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
DB		Hautmaki, R.D., et al. "Requirement for Macrophage Elastase for Cigarette Smoke-Induced Emphysema in Mice" (1997) Science 277:2002			
		Hessel, E.M., et al. "Bronchoconstriction and Airway Hyperresponsiveness after Ovalbumin Inhalation in Sensitized Mice" (1995) Eur J Pharmacol. 293:401			
		Hofstra, C.L., et al. "Antigen-stimulated Lung CD4+ Cells Produce IL-5, while Lymph Node CD4+ Cells Produce Th2 Cytokines Concomitant with Airway Eosinophilia and Hyperrespons			
		Jones, P.W., et al. "The St. George's Respiratory Questionnaire" (1991) Resp. Med. 85(suppl):25			
		Keast, D. et al. "A Survey of Pathological Changes Associated with Long-term High Tar Tobacco Smoke Exposure in a Murine Model" (1981) J. Pathol. 135:249			
		Keatings, V.M. et al. "Differences in Interleukin-8 and Tumor Necrosis Factor-a in Induced Sputum from Patients with Chronic Obstructive Pulmonary Disease or Asthma" Am J Resp			
		Keatings VM. "A Polymorphism in the Tumor Necrosis Factor-a Gene Promoter Region May Predispose to a Poor Prognosis in COPD*" (2000) Chest. 118:971-5			
		Kips et al. "Tumor Necrosis Factor Causes Bronchial Hyperresponsiveness in Rats" (1992) Am Rev Respir Dis 145:332			
		Nash et al. "Expression of Tumour Necrosis Factor-a in Cryptogenic Fibrosing Alveolitis" Histopathology. 1993 Apr;22(4):343-7			
DB		Ordonez CL. et al. "Increased Neutrophil Numbers and IL-8 Levels in Airway Secretions in Acute Severe Asthma" (2000) Am J Respir Crit Care Med 161:1185			

Examiner Signature	/David Blanchard/	Date Considered	08/31/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Application Number	10/623,076
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1644
Examiner Name	Not yet assigned
Attorney Docket Number	BBC-201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DB		Piquet et al. "Expression and Localization of Tumor Necrosis Factor-a and its mRNA in Idiopathic Pulmonary Fibrosis" (1993) Am J Pathol 143:651	
		Piquet et al. "Treatment by Human Recombinant Soluble TNF Receptor of Pulmonary Fibrosis Induced by Bleomycin or Silica in Mice" Eur Respir J. 1994 Mar;7(3):515-8	
		Piquet et al. "Requirement of Tumor Necrosis Factor for Development of Silica-Induced Pulmonary Fibrosis" Nature. 1990 Mar 15;344(6263):245-7	
		Piquet PF et al. "Tumor Necrosis Factor/Cachectin Plays a Key Role in Bleomycin-Induced Pneumopathy and Fibrosis" (1989) J Exp Med. 170:655-63	
		Pitsiou et al. "Tumor Necrosis Factor - alpha serum levels, weight loss and tissue oxygenation in Chronic Obstructive Pulmonary Disease" (2002) Respir Med.;96(8):594-8	
		Ray, P., et al. "Regulated Overexpression of Interleukin 11 in the Lung" (1997) J. Clin. Invest. 100:2501	
		Sakao S, et al. "Association of Tumor Necrosis Factor-a Gene Promoter Polymorphism with Low Attenuation Areas on High-Resolution CT in Patients with COPD" (2002) Chest. 122:4	
		Sakao S, et al. "Association of Tumor Necrosis Factor a Gene Promoter Polymorphism with the Presence of Chronic Obstructive Pulmonary Disease" (2001) Am J Respir Crit Care Med	
		Silver, R.M. "Interstitial Lung Disease of Systemic Sclerosis" (1995) Int Rev Immunol. 12:281	
DB		Smith et al. "Production and Function of Murine Macrophage Inflammatory Protein-1a in Bleomycin-Induced Lung Injury" (1994) J. Immunol. 153:4704	

Examiner Signature	/David Blanchard/	Date Considered	08/31/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known			
		Application Number	10/623,076		
		Filing Date	July 18, 2003		
		First Named Inventor	S. Banerjee		
		Art Unit	1644		
		Examiner Name	Not yet assigned		
Sheet	5	of	5	Attorney Docket Number	BBC-201

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
DB		Soler et al. "Airway Inflammation and Bronchial Microbial Patterns in Patients with Stable Chronic Obstructive Pulmonary Disease" Eur Respir J. 1999 Nov;14(5):1015-22			
		Takabatake et al. "The Relationship Between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor-a System in Patients with Chronic Obstructive Pulmonary Disease" (200			
		Takeyama et al. "Activation of Epidermal Growth Factor Receptors is Responsible for Mucin Synthesis Induced by Cigarette Smoke" (2001)Am J Physiol Lung Cell Mol Physiol. Jan;2			
		Takeyama et al. "Epidermal Growth Factor System Regulates Mucin Production in Airways" (1999) Proc Natl Acad Sci U S A. Mar 16;96(6):3081-6			
		Thomas PS, et al. "Tumor Necrosis Factor-a Increases Airway Responsiveness and Sputum Neutrophilia in Normal Human Subjects" (1995) Am J Respir Crit Care Med. 152:76-80			
		Thomas PS and Heywood G. "Effects of Inhaled Tumor Necrosis Factor alpha in Subjects with Mild Asthma" (2002) Thorax. 57:774-8			
		Tokuda, A., et al. "Pivotal Role of CCR1-Positive Leukocytes in Bleomycin-Induced Lung Fibrosis in Mice" (2000) J. Immunol. 164:2745			
		Vassallo et al. "Clinical Responses of Rheumatoid Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis Facto-a Inhibition" (2002) Chest. Sep;122(3):1093-6			
↓		Whyte et al. "Increased Risk of Fibrosing Alveolitis Associated with Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor-a Gene Polymorphisms" Am J Respir Crit Care Me			
DB		Zhang et al. "Enhanced IL-1b and Tumor Necrosis Factor-a Release and Messenger RNA Expression in Macrophages from Idiopathic Pulmonary Fibrosis or After Asbestos Exposure" J I			

Examiner Signature	/David Blanchard/	Date Considered	08/31/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.